文献速递血栓与止血

免疫调节药物联合TPO-RA治疗多重难治性ITP的西班牙ITP组经验

Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience.
PubMed 文献 · Br J Haematol · 2026-01-02

75例(77.3%)在中位14天起效,既往治疗失败线与应答呈负相关(Rho=-0.290,p=0.009),中位随访840天后35例(46.7%)复发。联合治疗可作为多重难治性ITP的替代选择。

要点

  • IS/IM联合TPO-RA治疗多重难治性ITP的应答率为77.3%,中位起效时间14天。
  • 既往治疗失败线越多,联合治疗应答越差(Rho=-0.290,p=0.009)。
  • 应答者中46.7%复发,慢性ITP患者复发更频繁;再次联合治疗应答与复发模式相似。

核心结论

  • IS/IM联合TPO-RA可作为多重难治性ITP的替代治疗选择。

主要发现

  • 75例(77.3%)患者应答,中位(IQR)起效时间14(7-52)天。
  • 既往失败治疗线与应答呈负相关(Rho=-0.290,p=0.009)。
  • 中位(IQR)随访840(448-1054)天后,75例应答者中35例(46.7%)复发,中位(IQR)复发时间197(47-402)天;慢性ITP患者复发更频繁。
  • 报告3例血栓栓塞事件和14例需住院的感染,均无致命性。

临床怎么用

  • 对≥3线治疗失败的多重难治性ITP患者,可考虑IS/IM联合TPO-RA治疗。
  • 治疗前应评估既往治疗失败线数,失败线越多应答可能性越低。
  • 应答后需监测复发,尤其慢性ITP患者;复发后可再次尝试联合治疗。

局限性

  • 本研究为回顾性观察研究,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multirefractory immune thrombocytopenia (ITP) is difficult to manage. The simultaneous administration of an immunosuppressive/immunomodulatory drug (IS/IM) and a thrombopoietin receptor agonist (TPO-RA) is increasingly used. We present the experience of the Spanish ITP Group in this retrospective, observational study. Ninety-seven patients with ≥3 failed treatment lines were administered combination therapy (CT) with an IS/IM and a TPO-RA between January 2021 and December 2023. The IS/IMs were steroids, purine synthesis inhibitors and fostamatinib. The TPO-RAs were romiplostim, eltrombopag and avatrombopag. Seventy-five (77.3%) patients responded to treatment in a median (interquartile range [IQR]) time of 14 (7-52) days. An inverse correlation between previous failures and response was observed (Rho = -0.290, p = 0.009). After 840 (448-1054) days, relapse was reported in 35 (46.7%) of 75 responders (time to relapse: 197 [47-402] days). Relapse was more frequent in chronic ITP patients. Twenty-one patients received a second CT after failure of the first one. Eleven were administered a third CT for the same reason. Response and relapse were similar to those observed with the first CT. Three thromboembolic events and 14 infections that required hospitalization were reported, none fatal. The combination of IS/IMs and TPO-RAs arises as an alternative option of treatment in multirefractory ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mingot-Castellano ME, Alcalde-Mellado P, Entrena-Ureña L, et al. Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience. Br J Haematol. 2026. PMID: 41480972. doi:10.1111/bjh.70306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。